Patient and site characteristics associated with pirfenidone and nintedanib use in the United States; an analysis of idiopathic pulmonary fibrosis patients enrolled in the Pulmonary Fibrosis Foundation Patient Registry

Table 3 Final multivariable model for anti-fibrotic use

Characteristic:	Coefficient	Odds ratio	95% Confidence Interval	p-value
Age (per year increase)^a	−0.024	0.974	0.956–0.992	0.0086
Age² (per year increase, squared)^a	− 0.001	0.999	0.998–0.999	0.0114
Days since diagnosis (per unit increase in log days)	0.129	1.138	1.088–1.191	< 0.0001
Oxygen use	0.472	1.604	1.178–2.183	0.0027
DLCO (percent-predicted, per 10%)	−0.154	0.896	0.785–0.937	0.0007
(Patient) Clinical trial participation in last 12mo.	0.451	1.569	1.014–2.429	0.0433

^aAge was centered on age 70
Abbreviations: Idiopathic Pulmonary Fibrosis (IPF); diffusion limitation for carbon monoxide (DLCO); months (mo)

ISSN: 1465-993X